Skip to content

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.68B+8.8%
Labcorp Holdings logo
Labcorp HoldingsLH
$278M+30.5%
Quest Diagnostics logo
Quest DiagnosticsDGX
$264M+12.3%
NeoGenomics logo
NeoGenomicsNEO
-$17.11M+34.0%
Natera, Inc. logo
Natera, Inc.NTRA
-$85.09M-27.1%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
-$125.92M-85.1%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$552.11M-7.1%
Enterprise value$536.92M+0.7%
P/S1.7×-0.3×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s net income?
Fulgent Genetics, Inc. (FLGT) reported net income of -$25.27M in Q1 2026.
How has Fulgent Genetics, Inc.'s net income changed year-over-year?
Fulgent Genetics, Inc.'s net income decreased by 112.4% year-over-year, from -$11.9M to -$25.27M.
What is the long-term trend for Fulgent Genetics, Inc.'s net income?
Over 4 years (2021 to 2025), Fulgent Genetics, Inc.'s net income has grown at a -40.9% compound annual growth rate (CAGR), from $506.24M to -$61.63M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.